natgillin/translations-raw huggingface dataset:
In clinical trials of antiretroviral treatment naive patients treated with boosted atazanavir, the I50L substitution did not emerge in any patient without baseline PI substitutions. 
U kliničkim ispitivanjima antiretrovirusnog liječenja pomoću pojačanog atazanavira u bolesnika koji prethodno nisu bili liječeni, supstitucija I50L nije se pojavila niti u jednog bolesnika koji na početku nije imao supstituciju za rezistenciju na inhibitore proteaze.
30 hard capsules. 
30 tvrdih kapsula.
Dose related asymptomatic prolongations in PR interval with atazanavir have been observed in clinical studies. 
U kliničkim je ispitivanjima opaženo asimptomatsko produljenje PR intervala povezano s dozom atazanavira.
Co- administration of atazanavir /ritonavir and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.4). 
Ne preporučuje se istovremena primjena atazanavira s ritonavirom i ovih glukokortikoida, osim ako je moguća korist od liječenja veća od rizika od sistemskih učinaka kortikosteroida (vidjeti dio 4.4).
a and at Week 96 (Study 045) 
Tablica 6: Ishodi djelotvornosti u 48. tjednu a i 96. tjednu (Ispitivanje 045)
CD4 Mean Change from Baseline, cells/mm All patients 
CD4 prosječna promjena od početne vrijednosti, stanice/mm Svi bolesnici
common: fatigue; uncommon: chest pain, malaise, pyrexia, asthenia; rare: gait disturbance a These adverse reactions were identified through post-marketing surveillance, however, the frequencies were estimated from a statistical calculation based on the total number of patients exposed to atazanavir in randomised controlled and other available clinical trials (n = 2321). 
Ove su nuspojave utvrđene u razdoblju nakon stavljanja lijeka u promet, premda, učestalost je procijenjena statističkim izračunom na temelju ukupnog broja bolesnika izloženih atazanaviru u randomiziranim kontroliranim i drugim dostupnim kliničkim ispitivanjima (n = 2321).
This medicine comes in blister packs containing 30 or 30 x 1 (unit dose) capsules or in bottles containing 30 or 90 hard capsules. 
Lijek je dostupan u blister pakiranjima koja sadrže 30 kapsula ili 30 x 1 (jedinične doze) kapsulu ili u boci koja sadrži 30 ili 90 tvrdih kapsula.
No significant effect on methadone concentrations was observed. 
Nisu opaženi značajni učinci na koncentraciju metadona.
Alternative antiretroviral therapy to Atazanavir Mylan may be considered if jaundice or scleral icterus is unacceptable to a patient. 
Može se razmotriti primjena drugih antiretrovirusnih lijekova ako su žutilo kože ili sklera bolesniku neprihvatljivi.
Co-administration of voriconazole and Atazanavir Mylan with ritonavir is not recommended, unless an assessment of the benefit/risk justifies the use of voriconazole. 
Ne preporučuje se istovremena primjena vorikonazola i lijeka Atazanavir Mylan s ritonavirom, osim ako procjena omjera koristi i rizika opravdava primjenu vorikonazola.
In case of withdrawal of ritonavir from the recommended atazanavir-boosted regimen (see section 4.4) 
Ako se ritonavir izostavi iz preporučenog režima liječenja atazanavirom pojačanim ritonavirom (vidjeti dio 4.4)
Ethinyloestradiol Cmax ↓16% (↓26% 
Etinilestradiol Cmax ↓16% (↓26%
(300 mg/100 mg once daily) n=440 
(300 mg/100 mg jedanput na dan) n=440
The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with proton pump inhibitors. 
Mehanizam interakcije je smanjena topljivost atazanavira s povišenjem želučanog pH zbog inhibitora protonske pumpe.
Co-administration with grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination (used to treat chronic hepatitis C infection) (see section 4.5). 
Istodobna primjena s lijekovima koji sadrže grazoprevir, uključujući fiksnu kombinaciju elbasvira/grazoprevira (koja se koristi u liječenju kronične infekcije virusom hepatitisa C) (vidjeti dio
30 x 1 hard capsules. 
30 x 1 tvrda kapsula.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP BLISTERI ZA TVRDE KAPSULE
increase in the concentration of these benzodiazepines. 
Istovremena primjena atazanavira može jako povećati koncentracije ovih benzodiazepina.
If you stop taking Atazanavir Mylan 
Ako prestanete uzimati Atazanavir Mylan
60 hard capsules. 
60 tvrdih kapsula.
Co-administration of Atazanavir Mylan with nevirapine or efavirenz is not recommended (see section 4.5). 
Ne preporučuje se istovremena primjena lijeka Atazanavir Mylan s nevirapinom ili efavirenzom (vidjeti dio 4.5).
Efavirenz 600 mg once daily 
Efavirenz 600 mg jedanput na dan
Didanosine AUC ↓34% (↓41% 
Didanozin AUC ↓34% (↓41% ↓27%)
Elbasvir concentrations were increased when co-administered with atazanavir/ritonavir. 
Koncentracije elbasvira bile su povišene s istodobnom primjenom atazanavira/ritonavira.
Nevirapine 200 mg twice daily 
Nevirapin 200 mg dvaput na dan
200 mg capsules 
200 mg kapsule
Midazolam and triazolam are extensively metabolised by CYP3A4. 
Midazolam i triazolam opsežno metabolizira enzim CYP3A4.
Didanosine Cmax ↓38% (↓48% 
Didanozin Cmax ↓38% (↓48% ↓26%)
For patients not taking tenofovir, if atazanavir 300 mg/ritonavir 100 mg and H2-receptor antagonists are co-administered, a dose equivalent to famotidine 20 mg twice daily should not be exceeded. 
300 mg/ritonavir 100 mg primjenjuju istovremeno s antagonistima H2 receptora, ne smije se prekoračiti doza jednaka dozi famotidina od 20 mg dvaput na dan.
300 mg capsules 
300 mg kapsule
The co-administration of stavudine with atazanavir is not expected to significantly alter the exposure of stavudine. 
Ne očekuje se da će istovremena primjena stavudina i atazanavira značajno promijeniti izloženost stavudinu.
Do not take Atazanavir Mylan 
Nemojte uzimati Atazanavir Mylan
Due to phenytoin/phenobarbital inducing effect, a reduction in atazanavir exposure cannot be ruled out combination with atazanavir /ritonavir. 
Zbog inducirajućeg učinka fenitoina/fenobarbitala, ne može se isključiti smanjena izloženost atazanaviru.
If you forget to take Atazanavir Mylan 
Ako ste zaboravili uzeti Atazanavir Mylan
Each capsule contains 84 mg lactose monohydrate 
Jedna kapsula sadrži 84 mg laktoza hidrata 200 mg kapsule
Hyperbilirubinaemia 
Hiperbilirubinemija
CD4 Mean Change from Baseline, cells/mm by Baseline Characteristic 
CD4 prosječna promjena od početne vrijednosti, stanice/mm prema početnim značajkama
Fluconazole 200 mg once daily 
Flukonazol 200 mg jedanput na dan
Patients with coexisting conditions 
Bolesnici s drugim istovremeno prisutnim bolestima
Grazoprevir concentrations were greatly increased when co-administered with atazanavir/ritonavir. 
Koncentracije grazoprevira značajno su porasle kada je primjenjivan istodobno s atazanavirom/ritonavirom.
ANTI-RETROVIRALS 
ANTIRETROVIRUSNI
, toxic skin eruptions a,b drug rash with eosinophilia and systemic symptoms (DRESS) syndrome a,b 
, izbijanje kožnih promjena uzrokovano toksičnim učinkom lijekaa,b, medikamentozni osip s eozinofilijom i sistemskim simptomima (DRESS)
Sildenafil, when used for the treatment of pulmonary arterial hypertension, is contraindicated (see section 
Sildenafil je kontraindiciran kad se primjenjuje za liječenje plućne arterijske hipertenzije (vidjeti dio 4.3).
This medicine comes in blister packs containing 30, 60 or 60 x 1 (unit dose) capsules or in bottles containing 60 hard capsules. 
Lijek je dostupan u blister pakiranjima koja sadrže 30, 60 kapsula ili 60 x 1 (jedinične doze) kapsulu ili u boci koja sadrži 60 tvrdih kapsula.
However, Atazanavir Mylan is not recommended in patients undergoing haemodialysis (see sections 4.2 and 5.2). 
Međutim, Atazanavir Mylan se ne preporučuje u bolesnika na hemodijalizi (vidjeti dijelove 4.2 i 5.2).
Co-administration of voriconazole and atazanavir with ritonavir is not recommended unless an assessment of the benefit/risk to the patient justifies the use of voriconazole (see section 4.4). 
Ne preporučuje se istovremena primjena vorikonazola i atazanavira s ritonavirom osim kad procjena omjera koristi i rizika za bolesnika opravdava primjenu vorikonazola (vidjeti dio 4.4).
reduced solubility of atazanavir with increasing pH related to the presence of anti-acid agent in didanosine buffered tablets. 
Mehanizam interakcije je smanjenje topljivosti atazanavira s povećanjem pH povezanim s prisutnošću antacida u puferiranim tabletama didanozina.
Each capsule contains 112 mg lactose monohydrate 
Jedna kapsula sadrži 112 mg laktoza hidrata 300 mg kapsule
Co-administration of Atazanavir Mylan with proton pump inhibitors is not recommended (see section 4.5). 
Ne preporučuje se istovremena primjena lijeka Atazanavir Mylan s inhibitorima protonske pumpe (vidjeti dio 4.5).
Co-administration of diltiazem and atazanavir /ritonavir has not been studied. 
Istovremena primjena diltiazema i atazanavira s ritonavirom nije ispitana.
Atazanavir Mylan is contraindicated in patients with severe hepatic insufficiency (see sections 4.2, 4.4 and 5.2). 
Atazanavir Mylan je kontraindiciran u bolesnika s teškom insuficijencijom jetre (vidjeti dijelove 4.2, 4.4 i 5.2).
Concentrations of atazanavir with or without ritonavir are expected to be increased in patients with moderately or severely impaired hepatic function (see sections 4.2, 4.3, and 4.4). 
U bolesnika s umjereno do teško oštećenom funkcijom jetre očekuju se povišene koncentracije atazanavira primijenjenog s ritonavirom ili bez njega (vidjeti dijelove 4.2, 4.3 i 4.4).
• chest pain, malaise (generally feeling unwell), fever 
• bol u prsištu, malaksalost (opće loše stanje), vrućica
Symptoms of gallbladder problems may include pain in the right or middle upper stomach area, nausea, vomiting, fever or yellowing your skin or the white part of your eyes. 
• Manje često mogu se pojaviti problemi sa žučnim kamencima u osoba koje uzimaju lijek Atazanavir Mylan . Simptomi problema sa žučnim kamencima mogu uključivati bol u desnom ili srednjem gornjem dijelu trbuha, mučninu, povraćanje, vrućicu ili žutilo kože ili bjeloočnica.
The mechanism of amiodarone or systemic lidocaine/atazanavir interaction is CYP3A inhibition. 
Mehanizam interakcije amiodarona ili sistemskog lidokaina s atazanavirom je inhibicija enzima CYP3A.
• vomiting, diarrhoea, abdominal pain (stomach pain of discomfort), nausea, dyspepsia (indigestion) 
• povraćanje, proljev, bol u trbuhu (bol ili nelagoda u želucu), mučnina, dispepsija (probavne tegobe)
This medicine comes in blister packs containing 60 or 60 x 1 (unit dose) capsules or in bottles containing 60 hard capsules. 
Lijek je dostupan u blister pakiranjima koja sadrže 60 kapsula ili 60 x 1 (jedinične doze) kapsulu ili u boci koja sadrži 60 tvrdih kapsula.
For treatment-naive paediatric patients, the mean baseline CD4 cell count was 344 cells/mm 
U pedijatrijskih bolesnika koji prethodno nisu bili liječeni, prosječni početni broj CD4 stanica bio je 344 stanice/mm (raspon: 2 do 800 stanica/ mm
ANTIFUNGALS Ketoconazole 200 mg once daily 
Ketokonazol 200 mg jedanput na dan
If atazanavir/ritonavir with both tenofovir disoproxil fumarate and an H2-receptor antagonist are co-administered, a dose increase of atazanavir to 400 mg with 100 mg of ritonavir is recommended. 
Za bolesnike koji uzimaju tenofovirdizoproksilfumarat, ako se atazanavir /ritonavir primjenjuju istovremeno s tenofovirdizoproksilfumaratom i antagonistom H2 receptora, preporučuje se povišenje doze atazanavira na 400 mg sa 100 mg ritonavira.
* When compared to Atazanavir 300 mg/ritonavir 100 mg once daily in the evening without efavirenz. 
* Kad je uspoređivan s atazanavirom 300 mg/ritonavirom 100 mg jedanput na dan, navečer, bez efavirenza.
Atazanavir is metabolised principally by CYP3A4. 
Atazanavir uglavnom metabolizira enzim CYP3A4.
HCV Protease Inhibitors Boceprevir 800 mg three times daily 
Boceprevir 800 mg triput na dan
Atazanavir is metabolised in the liver through CYP3A4. 
Atazanavir se metabolizira u jetri putem enzima CYP3A4.
* When compared to atazanavir 300 mg once daily with ritonavir 100 mg once daily. 
* Kad se uspoređuje s atazanavirom 300 mg jedanput na dan u kombinaciji s ritonavirom 100 mg jedanput na dan.
Hepatic transaminase elevations that occur with elevated bilirubin in patients receiving Atazanavir Mylan should be evaluated for alternative aetiologies. 
Potrebno je provjeriti alternativne uzroke povišenja jetrenih transaminaza koje može nastati uz povišenje bilirubina u bolesnika koji primaju Atazanavir Mylan.
using PDE5 inhibitors for erectile dysfunction with atazanavir (see section 4.4). 
Bolesnike treba upozoriti na ove moguće nuspojave kad se inhibitori PDE5 za erektilnu disfunkciju uzimaju istovremeno s atazanavirom (vidjeti dio 4.4).
Mean baseline CD4 cell count was 214 cells/mm 
Prosječni broj CD4 stanica na početku iznosio je 214 stanica/mm
uncommon: nephrolithiasis a, haematuria, proteinuria, pollakiuria, interstitial nephritis, chronic kidney disease a; 
manje često: nefrolitijaza a, hematurija, proteinurija, polakizurija; intersticijalni nefritis; kronična bubrežna bolest a rijetko: bubrežni bolovi
common: ocular icterus 
često: ikterus bjeloočnica
Co-administration of salmeterol and Atazanavir Mylan is not recommended (see section 4.5). 
Ne preporučuje se istovremena primjena salmeterola i lijeka Atazanavir Mylan (vidjeti dio 4.5).
Omeprazole 20 mg once daily 
Famotidin 20 mg dvaput na dan
Mylan B.V., Dieselweg 25, 3752 LB Bunschoten, The Netherlands 
Mylan Hungary Kft, Mylan utca 1, Komárom, H-2900, Mađarska Mylan B.V., Dieselweg 25, 3752 LB Bunschoten, Nizozemska
The capsule shell and printing ink contain titanium dioxide (E171), indigo carmine (E132), iron oxide yellow (E172), patent blue V (E131), gelatin, shellac, propylene glycol, concentrated ammonia solution, iron oxide black (E172), potassium hydroxide. 
Ovojnica kapsule i tinta za označavanje sadrže titanijev dioksid (E171), indigo karmin (E132), žuti željezov oksid (E172), boju patent blue V (E131), želatinu, šelak, propilenglikol, koncentriranu otopinu amonijaka, crni željezov oksid (E172), kalijev hidroksid.
Laboratory abnormalities 
abnormalni snovi
Table 1: Dose for paediatric patients (6 to less than 18 years of age and weighing at least 15 kg) for 
Tablica 1: Doza Atazanavir Mylan kapsula s ritonavirom za pedijatrijske bolesnike (u dobi od 6 do manje od 18 godina i tjelesne težine od najmanje 15 kg) Tjelesna težina (kg)
Co-administration of atazanavir and indinavir is not recommended (see section 4.4). 
Ne preporučuje se istovremena primjena atazanavira i indinavira (vidjeti dio 4.4).
Chronic kidney disease in HIV-infected patients treated with atazanavir, with or without ritonavir, has been reported during postmarketing surveillance. 
Tijekom praćenja nakon stavljanja lijeka u promet prijavljena je kronična bubrežna bolest u bolesnika zaraženih HIV-om liječenih atazanavirom, sa ili bez ritonavira.
There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in type A and B haemophiliac patients treated with protease inhibitors. 
U osoba s hemofilijom A i B liječenih inhibitorima proteaze zabilježeni su slučajevi pojačanog krvarenja, uključujući spontani nastanak kožnih hematoma i hemartroze.
Titanium dioxide (E171) Patent blue V (E131) Gelatin 
Titanijev dioksid (E171) Boja Patent blue V (E131) Želatina
For oral use. 
Način primjene Za peroralnu primjenu.
Co-administration of lamotrigine and atazanavir/ritonavir may decrease lamotrigine plasma concentrations due to UGT1A4 induction. 
Zbog indukcije UGT1A4, istodobna primjena lamotrigina i atazanavira s ritonavirom može sniziti koncentracije lamotrigina u plazmi.
Ethinyloestradiol AUC ↑48% 
Etinilestradiol AUC ↑48% (↑31%
Atazanavir Mylan 150 mg hard capsules Atazanavir Mylan 200 mg hard capsules Atazanavir Mylan 300 mg hard capsules atazanavir 
Atazanavir Mylan 150 mg tvrde kapsule Atazanavir Mylan 200 mg tvrde kapsule Atazanavir Mylan 300 mg tvrde kapsule atazanavir
(atazanavir 400 mg once daily) 
(atazanavir 400 mg jedanput na dan)
How to take Atazanavir Mylan 
Kako uzimati Atazanavir Mylan
Hyperbilirubinaemia (an increase in the level of bilirubin in the blood) has occurred in patients receiving atazanavir. 
U bolesnika koji uzimaju atazanavir može nastati hiperbilirubinemija (povišena razina bilirubina u krvi).
Atazanavir Mylan 200 mg capsules are blue and greenish-blue opaque hard shell gelatin capsules filled with white to pale yellow powder and approximately 21.4 mm in length. 
Atazanavir Mylan 200 mg kapsule su plave i zelenkastoplave neprozirne tvrde želatinske kapsule punjene bijelim do blijedožutim praškom i duljine približno 21,4 mm.
however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4). 
Međutim, vrijeme prijave pojave tih bolesti je vrlo varijabilno jer se mogu dogoditi i više mjeseci nakon početka liječenja.
Iron oxide yellow (E172) Iron oxide red (E172) Titanium dioxide (E171) Gelatin 
Žuti željezov oksid (E172) Crveni željezov oksid (E172) Titanijev dioksid (E171) Želatina
Tel: +386 1 236 31 85 
GSP Proizvodi d.o.o. Tel: +386 1 236 31 85
Atazanavir Mylan 300 mg capsules are red and greenish-blue opaque hard shell gelatine capsules filled with white to pale yellow powder and approximately 23.5 mm in length. 
Atazanavir Mylan 300 mg kapsule su crvene i zelenkastoplave neprozirne tvrde želatinske kapsule punjene bijelim do blijedožutim praškom i duljine približno 23,5 mm.
Treatment-Naive Atazanavir Capsules/ritonavir (300 mg/100 mg once daily) n=16 
Bolesnici koji prethodno nisu bili liječeni kapsulama atazanavira i ritonavirom (300 mg/100 mg jedanput na dan) n=16
No dosage adjustment is needed in patients with renal impairment. 
U bolesnika s oštećenjem bubrega nije potrebna prilagodba doze.
Pravastatin is not metabolised by CYP3A4. 
Pravastatin se ne metabolizira putem enzima CYP3A4.
Atazanavir Mylan 200 mg hard capsules are blue and greenish-blue opaque capsules with ‘MYLAN' over ‘AR200' printed in black ink on cap and body. 
Atanazavir Mylan 200 mg tvrde kapsule su plave i zelenkastoplave neprozirne kapsule na kojima je otisnuto „MYLAN” iznad „AR200” crnom tintom na kapici i tijelu.
The mechanism of the clarithromycin/atazanavir interaction is CYP3A4 inhibition. 
Mehanizam interakcije klaritromicin/atazanavir je inhibicija CYP3A4.
It inhibits CYP3A4. 
Atazanavir inhibira enzim CYP3A4.
* In a combined analysis, atazanavir 300 mg and ritonavir 100 mg (n=33) was compared to 
* U kombiniranoj analizi, atazanavir 300 mg s ritonavirom 100 mg (n=33) uspoređen je s atazanavirom 400 mg bez ritonavira (n=28).
Atazanavir Mylan 150 mg hard capsules Atazanavir Mylan 200 mg hard capsules Atazanavir Mylan 300 mg hard capsules 
Atazanavir Mylan 150 mg tvrde kapsule Atazanavir Mylan 200 mg tvrde kapsule Atazanavir Mylan 300 mg tvrde kapsule
The capsule shell and printing ink contain iron oxide red (E172), titanium dioxide (E171), patent blue V (E131), gelatin, shellac, propylene glycol, concentrated ammonia solution, iron oxide black (E172), potassium hydroxide. 
Ovojnica kapsule i tinta za označavanje sadrže crveni željezov oksid (E172), titanijev dioksid (E171), boju patent blue V (E131), želatinu, šelak, propilenglikol, koncentriranu otopinu amonijaka, crni željezov oksid (E172), kalijev hidroksid.
Co-administration with atazanavir may result in increased concentrations of salmeterol and an 
Istovremena primjena s atazanavirom može rezultirati povišenim koncentracijama salmeterola i pojačanim nuspojavama povezanima sa salmeterolom.
The mechanism of this interaction is CYP3A4 inhibition. 
Mehanizam ove interakcije je inhibicija enzima CYP3A4.
Body Weight (kg) 
(kg)
How to store Atazanavir Mylan 
Kako čuvati Atazanavir Mylan
The mechanism of interaction between atazanavir and ritonavir is CYP3A4 inhibition. 
Mehanizam interakcije između atazanavira i ritonavira je inhibicija enzima CYP3A4.
Nephrolithiasis has been reported in patients receiving atazanavir (see section 4.8). 
U bolesnika koji primaju atazanavir zabilježena je nefrolitijaza (vidjeti dio 4.8).
Cholelithiasis has been reported in patients receiving atazanavir (see section 4.8). 
U bolesnika koji primaju atazanavir zabilježena je kolelitijaza (vidjeti dio 4.8).
Co-administration of alfuzosin with atazanavir is contraindicated (see section 4.3) 
Istovremena primjena alfuzosina i atazanavira je kontraindicirana (vidjeti dio 4.3)
3) and the mean baseline plasma HIV-1 RNA level was 4.4 log10 copies/ml (range: 2.6 to 5.88 log10 copies/ml). 
3), a prosječna početna vrijednost HIV 1 RNK u plazmi bila je 4,67 log10 kopija/ml (raspon: 3,70 do 5,00 log10 stanica/ml).
CARDIOVASCULAR AGENTS Antiarrhythmics 
KARDIOVASKULARNI LIJEKOVI
Atazanavir Mylan 300 mg hard capsules are red and greenish-blue opaque capsules with ‘MYLAN' over ‘AR300' printed in black ink on cap and body. 
Atanazavir Mylan 300 mg tvrde kapsule su crvene i zelenkastoplave neprozirne kapsule na kojima je otisnuto „MYLAN” iznad „AR300” crnom tintom na kapici i tijelu.
The capsules are axially printed with ‘MYLAN' over ‘AR150' in black ink on cap and body. 
Na kapsulama je uzduž osi otisnuto „MYLAN” iznad „AR150” crnom tintom na kapici i tijelu.
Ritonavir is used as a booster of atazanavir pharmacokinetics (see sections 4.5 and 5.1). 
Ritonavir se koristi kao pojačivač farmakokinetike atazanavira (vidjeti dijelove 4.5 i 5.1). (Vidjeti i 'Prekid primjene ritonavira samo pod restriktivnim uvjetima' u dijelu 4.4).
Atazanavir Mylan 150 mg hard capsules are greenish-blue and blue opaque capsules with ‘MYLAN' over ‘AR150' printed in black ink on cap and body. 
Atanazavir Mylan 150 mg tvrde kapsule su zelenkastoplave i plave neprozirne kapsule na kojima je otisnuto „MYLAN” iznad „AR150” crnom tintom na kapici i tijelu.
Hepatic impairment 
• bubrežni bolovi
Tacrolimus 
Salmeterol
METHOD AND ROUTE OF ADMINISTRATION 
NAČIN I PUT PRIMJENE LIJEKA
Stevens-Johnson syndrome (SJS), erythema multiforme, toxic skin eruptions and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported in patients receiving atazanavir. 
U bolesnika koji primaju atazanavir zabilježeni su Stevens-Johnsonov sindrom (SJS), multiformni eritem, toksične kožne erupcije i medikamentozni osip s eozinofilijom i sistemskim simptomima (DRESS).
Serum concentrations of verapamil may be increased by atazanavir due to CYP3A4 inhibition. 
Atazanavir može povisiti koncentracije verapamila u serumu zbog inhibicije enzima CYP3A4.
Atazanavir Mylan 150 mg capsules are greenish-blue and blue opaque hard shell gelatin capsules filled with white to pale yellow powder and approximately 19.3 mm in length. 
Atazanavir Mylan 150 mg kapsule su zelenkastoplave i plave neprozirne tvrde želatinske kapsule punjene bijelim do blijedožutim praškom i duljine približno 19,3 mm.
The combination of Atazanavir Mylan with atorvastatin is not recommended (see section 4.5). 
Ne preporučuje se istovremena primjena lijeka Atazanavir Mylan s atorvastatinom (vidjeti dio 4.5).
Co-administration of nevirapine and atazanavir is not recommended (see section 4.4) 
Ne preporučuje se istovremena primjena nevirapina i atazanavira (vidjeti dio 4.4)
(400 mg/ 100 mg twice daily) n=123 
100 mg dvaput na dan) n=123
The Summary of Product Characteristics for ritonavir must be consulted before initiation of therapy with Atazanavir Mylan and ritonavir. 
Prije početka terapije lijekom Atazanavir Mylan i ritonavirom potrebno je pročitati Sažetak opisa svojstava lijeka za ritonavir.
Ritonavir may decrease plasma levels of phenytoin and/or phenobarbital due to CYP2C9 and 
Zbog indukcije CYP2C9 i CYP2C19, primjena ritonavira može sniziti razine fenitoina i/ili fenobarbitala u plazmi.
Nephrolithiasis 
Nefrolitijaza
For patients who are taking tenofovir disoproxil fumarate, 
Kod bolesnika koji ne uzimaju tenofovir, ako se atazanavir
The mechanism of interaction is CYP3A4 inhibition. 
Mehanizam interakcije je inhibicija enzima CYP3A4.
Co-administration of efavirenz and atazanavir is not recommended (see section 4.4) 
Ne preporučuje se istovremena primjena efavirenza i atazanavira (vidjeti dio 4.4)
In HIV-infected patients with atazanavir/ritonavir at the recommended dose 300/100 mg once daily 
Primjena atazanavira/ritonavira u preporučenoj dozi od 300/100 mg jedanput na dan u bolesnika zaraženih HIV-om